Home › Trials › NCT07442006
Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 19 and up

Comparing blood sugar swings with different diabetes pill combinations in type 2 diabetes

Official title: A Multicenter Study to Evaluate Efficacy and Safety

Run by JW Pharmaceutical · NCT07442006 · Data updated 2026-11-12

This study will test whether different combinations of empagliflozin, metformin, linagliptin, or anagliptin reduce blood sugar swings in adults with type 2 diabetes who remain uncontrolled on metformin plus an SGLT2 inhibitor.

Quick facts

PhasePhase 4
Study typeInterventional
Ages19 Years and up
SexAll
Enrollment178 (estimated)
SponsorJW Pharmaceutical
Industry-sponsored
Locations1 site (Seoul)
StatusRecruiting
StartedOctober 29, 2025
Main results expectedMarch 31, 2027
Study endsMarch 31, 2027
Registry record updatedMarch 2, 2026
Trial IDNCT07442006 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with type 2 diabetes who have inadequate glycemic control despite taking metformin (≥1,000 mg/day) plus an SGLT2 inhibitor, and who do not have significant renal, hepatic, or advanced heart failure, are ideal candidates.

Probably not a fit

People with moderate-to-severe renal impairment (eGFR <45 mL/min/1.73m²), severe hepatic impairment, a history of metabolic acidosis, or NYHA class III/IV heart failure are unlikely to be eligible or to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, phase 4, interventional trial comparing several combination oral regimens in people with type 2 diabetes who have inadequate control on metformin and an SGLT2 inhibitor. Participants will be assigned to treatment arms that include combinations such as empagliflozin/metformin, empagliflozin/linagliptin, anagliptin, or metformin alone to observe effects on glycemic variability. Continuous glucose monitoring and routine safety labs will be used to measure day-to-day glucose fluctuations and adverse events. The trial focuses on both efficacy for reducing variability and the safety profile in a real-world treatment setting.

Why it matters

Potential benefit: If successful, it could identify combination regimens that reduce glucose variability and improve day-to-day blood sugar control while maintaining acceptable safety.

How similar studies have gone: Previous trials of SGLT2 plus DPP-4 inhibitor or metformin combinations have demonstrated improvements in HbA1c and some reductions in glycemic variability, so this approach builds on existing evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.

Exclusion Criteria:

* History of acute or chronic metabolic acidosis
* Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²)
* Severe hepatic impairment
* History of heart failure (NYHA Class III/IV)

Where it's running

  • The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
    Seoul, South Korea     Recruiting

Study contacts

  • Principal investigator: Sung Rae Kim — The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
  • Study coordinator: Saemi Kang
  • Email: kangsm@jwhealthcare.com
  • Phone: 82-2-840-6902

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Type 2 Diabetes Mellitus (T2DM) 68JW Pharmaceutical 6
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.